Dihydroxydihydro-beta-ionone glucoside

This compound is a megastigmane glucoside—an apocarotenoid-derived terpenoid conjugated to a beta-D-glucopyranose sugar moiety—that displays weak anti-inflammatory activity, with inhibitory potency reported at IC50 values exceeding 100 µM in bioassay screening. Current evidence is limited to phytochemical identification and preliminary in vitro bioactivity data, with no clinical trials or standardized dosing established for this specific molecule.

Origin & History

This megastigmane glucoside occurs as a minor phytochemical constituent in select flowering plants, most notably species within the genus Vitex (chaste tree family, Lamiaceae) and in the leaves of apple (Malus domestica), distributed across temperate and subtropical regions. It is not cultivated or concentrated as a primary crop product but is instead isolated as a trace metabolite from methanolic or aqueous-organic extracts of these plant tissues. Its biosynthesis follows the carotenoid degradation pathway common to many higher plants, producing apocarotenoid-derived terpenoid glycosides as secondary metabolites.

Historical & Cultural Context

This specific glucoside has no documented independent history of traditional use, as it was identified through modern phytochemical analysis rather than through the ethnobotanical record. Its source plants, particularly Vitex agnus-castus (chaste tree), have a rich history of use in European and Mediterranean herbal traditions dating back to ancient Greece, where Dioscorides and Hippocrates referenced the plant for hormonal and reproductive health applications. Apple (Malus domestica) leaf preparations have been used in folk medicine traditions across Europe and Central Asia as mild astringents and anti-inflammatory remedies, and the megastigmane content of these leaves may have contributed to such activities without historical practitioners being aware of the specific chemical constituents. The identification of this compound represents modern phytochemical science retroactively characterizing the chemistry underlying centuries-old botanical knowledge.

Health Benefits

- **Anti-Inflammatory Activity**: Grouped among megastigmane glucosides that exhibit measurable inhibitory activity in inflammation-related bioassays, though potency is modest with IC50 values above 100 µM, suggesting it contributes to the overall anti-inflammatory phytochemical profile of source plants rather than acting as a primary active agent.
- **Antioxidant Potential (Structural Inference)**: As an apocarotenoid glucoside, the molecule shares structural features with carotenoid degradation products known to scavenge reactive oxygen species; however, direct antioxidant data for this specific stereoisomer are not yet published.
- **Contribution to Plant Extract Bioactivity**: In complex plant extracts from Vitex species, megastigmane glucosides collectively contribute to the observed pharmacological activities attributed to these herbal preparations, suggesting a role in synergistic multi-compound effects.
- **Phytochemical Marker Utility**: The compound serves as a chemical marker for the characterization and quality control of Vitex and Malus domestica leaf extracts, supporting standardization efforts in herbal product development.
- **Potential Immunomodulatory Context**: Related megastigmane glycosides isolated from medicinal plants have demonstrated preliminary immunomodulatory properties in cellular assays; this compound's structural similarity positions it as a candidate for analogous investigation, pending dedicated studies.

How It Works

The anti-inflammatory activity of (3S,4R)-dihydroxy-7,8-dihydro-β-ionone 4-O-β-D-glucopyranoside has been attributed broadly to inhibitory effects in inflammation-screening assays at concentrations above 100 µM, but the specific molecular target—whether cyclooxygenase (COX-1/COX-2), lipoxygenase (LOX), NF-κB signaling, or cytokine production—has not been delineated in published literature. The glucopyranose moiety at the C-4 hydroxyl position is known to influence cellular uptake and membrane interaction in related glycosides by acting as a substrate for glucosidase-mediated hydrolysis, potentially releasing the aglycone form intracellularly where it may interact with lipophilic protein targets. The ionone-derived terpenoid core, a degradation product of carotenoid biosynthesis, shares structural features with sesquiterpenoid compounds that modulate oxidative stress responses through Nrf2 pathway activation in analogous systems. Without target-identification studies, the precise mechanism remains speculative and inferred from structural class analogy.

Scientific Research

Published research on this specific compound is extremely limited and consists almost entirely of phytochemical isolation reports and preliminary bioactivity screening data, representing the lowest tier of pharmacological evidence. No peer-reviewed clinical trials, randomized controlled trials, or even formal in vivo animal studies have been published for this molecule as an isolated entity; its bioactivity is inferred from bioassay panels where IC50 values exceeded 100 µM, indicating weak potency relative to reference anti-inflammatory agents. The compound has been identified in phytochemical profiling studies of Vitex species and Malus domestica leaves, where its structural characterization was confirmed by NMR spectroscopy and mass spectrometry, but pharmacokinetic or pharmacodynamic data are absent. The overall evidentiary base does not support conclusions about therapeutic efficacy, and investigators in this space have consistently noted the need for dedicated mechanistic and translational studies.

Clinical Summary

No clinical trials of any design have been conducted on (3S,4R)-dihydroxy-7,8-dihydro-β-ionone 4-O-β-D-glucopyranoside as an isolated compound or as a standardized ingredient. Available data originate exclusively from in vitro bioactivity screening panels reporting IC50 values greater than 100 µM for anti-inflammatory endpoints, a threshold generally considered low potency in drug discovery contexts. There are no reported outcomes related to efficacy, safety, tolerability, pharmacokinetics, or bioavailability in human or animal subjects for this specific molecule. Confidence in any clinical application is therefore negligible without foundational preclinical dose-response and mechanistic studies being completed first.

Nutritional Profile

As a minor phytochemical isolated from plant tissues, (3S,4R)-dihydroxy-7,8-dihydro-β-ionone 4-O-β-D-glucopyranoside does not constitute a nutritional ingredient in the conventional macronutrient or micronutrient sense. Its molecular weight is approximately 390–420 g/mol (consistent with megastigmane C13 terpenoid aglycone plus hexose sugar unit), and it contains no protein, fat, or appreciable caloric value at the trace concentrations found in plant tissue. The glucopyranose moiety contributes one unit of glucose upon hydrolysis, which is nutritionally insignificant at dietary exposure levels. Concentrations in source plant tissues have not been quantified in available literature, but megastigmane glucosides typically occur at sub-milligram per gram dry weight levels in plant extracts, rendering nutritional contribution negligible.

Preparation & Dosage

- **Isolation Form**: Obtained as a purified compound through methanolic extraction of plant material followed by silica gel, ODS, or Sephadex LH-20 column chromatography; not available as a consumer supplement ingredient.
- **Source Plant Extracts**: Vitex species (e.g., Vitex agnus-castus) standardized extracts are commercially available, but these are not standardized for this specific megastigmane glucoside content.
- **Research Grade**: Used in research settings as an isolated phytochemical at concentrations typically spanning 10–200 µM for in vitro assays; no effective human dose has been established.
- **Traditional Preparation**: Plants containing this compound (Vitex spp.) have historically been prepared as decoctions, tinctures, or dried berry preparations, but the contribution of this specific glucoside to efficacy has not been quantified.
- **Standardization**: No commercial product is currently standardized for this compound; its use as a standalone ingredient is not documented in pharmacopeial or regulatory frameworks.

Synergy & Pairings

No synergy data exist specifically for this compound, but within the context of Vitex agnus-castus extracts, megastigmane glucosides co-occur with iridoid glycosides (such as aucubin and agnuside) and flavonoids (such as vitexin and casticin), which collectively contribute to the anti-inflammatory and hormone-modulating activity attributed to that botanical. Apocarotenoid-class compounds like megastigmanes are structurally positioned to complement polyphenolic antioxidants through complementary radical-scavenging mechanisms, as seen with analogous terpenoid-polyphenol pairings in olive and rosemary extract research. Dedicated synergy studies for this specific glucoside in combination with other phytochemicals have not been conducted.

Safety & Interactions

No formal toxicology studies, adverse event reports, or safety evaluations have been published for (3S,4R)-dihydroxy-7,8-dihydro-β-ionone 4-O-β-D-glucopyranoside, and its safety profile is entirely uncharacterized at this time. Drug interactions cannot be predicted with confidence in the absence of cytochrome P450 inhibition or induction data, plasma protein binding studies, or transporter interaction assays for this molecule. Contraindications and pregnancy or lactation guidance are unknown; caution is warranted given the complete absence of human exposure data, and use during pregnancy should be avoided on precautionary grounds. Given that the compound occurs at trace levels within whole plant preparations (notably Vitex spp.) that themselves carry known safety considerations—including hormonal activity and potential drug interactions—consumers should consult a healthcare provider before using any extract of source plants.